News
SDZNY
70.98
-0.92%
-0.66
Mark Cuban calls for end to generic drug application fees to boost domestic manufacturing
Seeking Alpha · 21h ago
Sandoz Group AG Sponsored ADR (SDZNY) Upgraded to Buy: Here's Why
NASDAQ · 1d ago
Morgan Stanley Reaffirms Their Hold Rating on Sandoz Group Ltd (SDZXF)
TipRanks · 2d ago
Weekly Report: what happened at SDZNY last week (1124-1128)?
Weekly Report · 4d ago
Sandoz Launches Denosumab Biosimilars in Europe
Reuters · 4d ago
Weekly Report: what happened at SDZNY last week (1117-1121)?
Weekly Report · 11/24 09:52
Sandoz Wins European Commission Approval for Afqlir Biosimilar Aflibercept
Reuters · 11/24 06:21
PRESS DIGEST-Canada - Nov 21
Reuters · 11/21 13:49
Pfizer: Is This Pharma Giant Finally A Bargain
Seeking Alpha · 11/19 20:51
Sandoz Group Ltd (SDZXF) Gets a Buy from Kepler Capital
TipRanks · 11/19 01:45
Mirum Pharmaceuticals Sues Sandoz Over Proposed Generic Livmarli
Reuters · 11/17 21:53
Sandoz price target raised to CHF 60 from CHF 55 at Deutsche Bank
TipRanks · 11/17 19:25
Diamond Hill International Strategy Q3 2025 Portfolio Activity
Seeking Alpha · 11/17 14:05
Weekly Report: what happened at SDZNY last week (1110-1114)?
Weekly Report · 11/17 09:52
Sandoz Launches First FDA-Approved Multiple Sclerosis Biosimilar TYRUKO in US
Reuters · 11/17 06:02
Kepler Capital Keeps Their Buy Rating on Sandoz Group Ltd (SDZXF)
TipRanks · 11/14 01:46
Sandoz Group AG Laboratories Achieve My Green Lab Certification
Reuters · 11/13 09:25
UPDATE 1-Sandoz CEO expects Ozempic biosimilars to enter Canadian market in Q1, Q2
Reuters · 11/12 15:09
SANDOZ GROUP CEO EXPECTS DEMAND FROM DIABETES PATIENTS TO "BE WAY IN EXCESS" OF SUPPLY FOR SEMAGLUTIDE BIOSIMILAR IN CANADA
Reuters · 11/12 14:52
SANDOZ GROUP CEO RICHARD SAYNOR EXPECTS SEMAGLUTIDE BIOSIMILARS TO LAUNCH IN Q1, Q2 NEXT YEAR IN CANADA - INTERVIEW
Reuters · 11/12 14:52
More
Webull provides a variety of real-time SDZNY stock news. You can receive the latest news about Sandoz Group AG through multiple platforms. This information may help you make smarter investment decisions.
About SDZNY
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.